JG
SUPN icon

Jefferies Group’s Supernus Pharmaceuticals SUPN Stock Holding History

Jefferies Group’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-7,500
Closed -$235K – 2555
2017
Q1 		$235K Buy
+7,500
New +$201K ﹤0.01% 1951

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Jefferies Group's SUPN Position: Q4 2021 in Review

Jefferies Group sold out of Supernus Pharmaceuticals (SUPN) in Q4 2021, closing a stake of 100 shares — an estimated $2.67K sold.

Jefferies Group first reported a position in SUPN in Q2 2014 and held it in 14 quarters. The position peaked at $4.42M in Q3 2014. 235 funds tracked by Wall St. Rank hold SUPN as of Q4 2021.

  • Jefferies Group reported no remaining Supernus Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Jefferies Group sold 100 Supernus Pharmaceuticals shares in Q4 2021, an estimated $2.67K.
  • Jefferies Group first reported a position in Supernus Pharmaceuticals in Q2 2014 and held it in 14 quarters.
  • Jefferies Group's Supernus Pharmaceuticals position peaked at $4.42M in Q3 2014.
  • 235 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2021.

Based on Jefferies Group's 13F filing for Q4 2021, filed 14 Feb 2022.